The level of native and oxidized lipoprotein(a) in children with nephrotic syndrome

Clinical Biochemistry

Volumn 45, Issue 1-2, 2012, Pages 101-105

  Li, Han qing ^a   Wu, Jia ^a   Niu, Dong Mei ^a   Shi, Yong Hui ^a   Zhang, Chun ni ^a   Wang, Jun jun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Atherosclerosis; Lipoprotein(a); Lipoproteins; Nephrotic syndrome; Oxidative stress

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; OXIDIZED LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PREDNISONE; SERUM ALBUMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ARTICLE; ATHEROSCLEROSIS; CHILD; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; HUMAN; IDIOPATHIC DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; REMISSION; SINGLE DRUG DOSE; STEROID THERAPY; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; UROGENITAL SYSTEM PARAMETERS;

ALBUMINS; ATHEROSCLEROSIS; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNE SYSTEM; INFANT; KIDNEY; LIPIDS; LIPOPROTEIN(A); MALE; NEPHROTIC SYNDROME; OXIDATIVE STRESS; OXYGEN; REGRESSION ANALYSIS; REMISSION INDUCTION;

EID: 84855315087     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.11.002     Document Type: Article

References (40)

1. Scanu A.M., Lawn R.M., Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991, 115(3):209-218.
2. Terres W., Tatsis E., Pfalzer B., Beil F.U., Beisiegel U., Hamm C.W. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation 1995, 91(4):948-950.
3. Zhuang Y., Li J., Wang J. Apolipoprotein(a) phenotypes in cardiocerebrovasculor diseases. Chem Phys Lipids 1994, 107(2):133-136.
4. Wang J., Niu D., Meng Y., Han A., Li K., Zhang C. Plasma oxidized lipoprotein(a) and its immune complexes are present in newborns and children. Clin Chim Acta 2009, 407(1-2):1-5.
5. Wang J., Hu B., Kong L., Cai H., Zhang C. Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin Chim Acta 2008, 390(1-2):67-71.
6. Wang J., Zhang C., Meng Y., Han A., Gong J., Li K. Elevated concentrations of oxidized lipoprotein(a) are associated with the presence and severity of acute coronary syndromes. Clin Chim Acta 2009, 408(1-2):79-82.
7. Wang J., Han A., Meng Y., et al. Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: using different capture antibody against oxidized lipoprotein (a) or oxidized LDL. Clin Biochem 2010, 43(6):571-575.
8. Ece A., Atamer Y., Gürkan F., Bilici M., Koçyiǧit Y. Anti-oxidant status in relation to lipoproteins, leptin and pro-inflammatory cytokines in children with steroid-sensitive nephrotic syndrome. Nephrology 2004, 9(6):366-373.
9. Ece A., Atamer Y., Gurkan F., Davutoglu M., Kocyigit Y., Tutanc M. Paraoxonase, total antioxidant response and peroxide levels in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2005, 20(9):1279-1284.
10. El-Melegy N.T., Mohamed N.A., Sayed M.M. Oxidative modification of low-density lipoprotein in relation to dyslipidemia and oxidant status in children with steroid sensitive nephrotic syndrome. Pediatr Res 2008, 63(4):404-409.
11. Zima T., Tesar V., Stípek S., et al. The influence of cyclosporin on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Nephron 1997, 75(4):464-468.
12. Hu P., Lu L., Hu B., Du P.F. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome. Scand J Clin Lab Invest 2009, 69(6):680-686.
13. Kawasaki Y., Suzuki J., Nozawa R., Suzuki S., Suzuki H. Prediction of relapse by plasma lipoprotein(a) concentration in children with steroid-sensitive nephrotic syndrome. Nephron 2002, 92(4):807-811.
14. Wang J., Zhuang Y., Yao X. Quantitation of plasminogen epitopes of serum lipoprotein(a) by sandwich enzyme linked immunosorbent assay. Clin Chim Acta 1997, 265(1):121-130.
15. Wang J., Zhang C., Gong J., Zhu Y., Fu L., Wang X., et al. Development of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a) by using purified human oxidized lipoprotein(a) autoantibodies as capture antibody. Clin Chim Acta 2007, 385(1-2):73-78.
16. Wang J., Qiang H., Zhang C., Liu X., Chen D., Wang S. Detection of IgG-bound lipoprotein(a) immune complexes in patients with coronary heart disease. Clin Chim Acta 2003, 327(1-2):115-122.
17. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
18. Kronenberg F. Dyslipidemia and nephrotic syndrome: recent advances. J Ren Nutr 2005, 15(2):195-203.
19. Merouani A., Levy E., Mongeau J.G., Robitaille P., Lambert M., Delvin E.E. Hyperlipidemic profiles during remission in childhood idiopathic nephrotic syndrome. Clin Biochem 2003, 36(7):571-574.
20. Kim H.J., Vaziri N.D. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inf lammation in chronic renal failure. Am J Physiol Renal Physiol 2010, 298(3):F662-F671.
21. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 2006, 290(2):F262-F272.
22. Vaziri N.D. Lipotoxicity and impaired HDL-mediated reverse cholesterol/lipid transport in chronic kidney disease. J Ren Nutr 2010, 20(5):S35-S43.
23. Shearer G.C., Stevenson F.T., Atkinson D.N., Jones H., Staprans I., Kaysen G.A. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 2001, 59(1):179-189.
24. Craig W.Y., Neveux L.M., Palomaki G.E., Cleveland M.M., Haddow J.E. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998, 44(11):2301-2306.
25. Dieplinger H., Kronenberg F. Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1). Wien Klin Wochenschr 1999, 111(1):5-20.
26. Wanner C., Rader D., Bartens W., Kramer J., Brewer H.B., Schollmeyer P., et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993, 119(4):263-269.
27. Kronenberg F., Lingenhel A., Lhotta K., et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int 2004, 65(2):606-612.
28. De Sain-Van Der Velden M.G., Reijngoud D.J., Kaysen G.A., et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998, 9(8):1474-1481.
29. Frischmann M.E., Kronenberg F., Trenkwalder E., et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007, 71(10):1036-1043.
30. Kwan B.C., Kronenberg F., Beddhu S., Cheung A.K. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007, 18(4):1246-1261.
31. Stenvinkel P., Heimburger O., Tuck C.H., Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998, 53(5):1336-1342.
32. Zimmermann J., Herrlinger S., Pruy A., Metzger T., Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55(2):648-658.
33. Stenvinkel P., Heimburger O., Paultre F., Diczfalusy U., Wang T., Berglund L., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999, 55(5):1899-1911.
34. Kronenberg F., Kuen E., Ritz E., et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000, 11(1):105-115.
35. Kronenberg F., Konig P., Neyer U., et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995, 6(1):110-120.
36. Keane W.F., Kasiske B.L., O'Donnel M.P. Lipids and progressive glomerulosclerosis: a model analogous to atherosclerosis. Am J Nephrol 1988, 8(4):261-271.
37. Kamireddy R., Kavuri S., Devi S., et al. Oxidative stress in pediatric nephrotic syndrome. Clin Chim Acta 2002, 325(1-2):147-150.
38. Kinra S., Rath B., Kabi B.C. Indirect quantification of lipid peroxidation in steroid responsive nephrotic syndrome. Arch Dis Child 2000, 82(1):76-78.
39. Hodson E.M., Willis N.S., Craig J.C. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2009, (3):CD001533.
40. Das U.N., Mohan I.K., Raju T.R. Effect of corticosteroids and eicosapentaenoic acid/docosahexaenoic acid on pro-oxidant and anti-oxidant status and metabolism of essential fatty acids in patients with glomerular disorders. Prostaglandins Leukot Essent Fatty Acids 2001, 65(4):197-203.